Canada Cancer Immunotherapy Market Size & Outlook
Canada cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Canada cancer immunotherapy market highlights
- The Canada cancer immunotherapy market generated a revenue of USD 3,449.8 million in 2023 and is expected to reach USD 6,953.0 million by 2030.
- The Canada market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 3,449.8 million |
| Market revenue in 2030 | USD 6,953.0 million |
| Growth rate | 10.5% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Canada accounted for 2.7% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 6,953.0 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.94% in 2023. Horizon Databook has segmented the Canada cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer remains a leading cause of mortality in Canada, having accounted for nearly 30% of all deaths in 2019. It is estimated that, on an average, 604 new cases are recorded and 225 patients die from cancer each day.
In 2019, breast, lung, prostate, and colorectal cancers accounted for 48% of all cancer incidence. Breast cancer ranked as the most prevalent disease among women (25%), while prostate cancer ranked first among men (20%).
There is a need for restructuring the healthcare system in Canada pertaining to the approval of novel drugs. Personalized healthcare strategies are faced with the challenges of adoption and access. For instance, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued a negative feedback for Bayer's Vitrakvi due to unconventional trial design.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada cancer immunotherapy market size, by product, 2018-2030 (US$M)
Canada Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
